Polycystic ovary syndrome: Evidence-Based Supplement Guide

Eleven of the 72 people in Avelor with a saved stack hold something taken for PCOS. It is the only condition covered so far that has a current international evidence-based guideline behind it (PMID 37580314), and that changes what this guide is for. It is not here to assemble the evidence from scratch. It is here to say where supplements sit relative to a guideline that already exists, and to be honest that for most of them the answer is "outside it". PCOS is a metabolic and psychological condition as much as a reproductive one, and the guide is written that way because the evidence is. A systematic review and meta-analysis informing the guideline update reported elevated clinical cardiovascular disease in PCOS (PMID 39119982). A separate systematic review and meta-analysis reported a high prevalence of moderate and severe depressive and anxiety symptoms (PMID 28333286). A general clinical review sets out the condition's reach across the lifespan (PMID 35934017), and a global prevalence meta-analysis gives the scale (PMID 38922413). Anyone whose mental picture of PCOS is only about periods and fertility is working from a narrower condition than the one described in the literature. Lifestyle is first-line in the guideline, and the useful finding is a negative one: no single diet wins. A systematic review examined lifestyle interventions in PCOS management (PMID 39861440), and a network meta-analysis ranked dietary interventions against each other rather than each against nothing (PMID 38388374). Among medicines, metformin has a systematic review and meta-analysis against placebo with and without lifestyle change (PMID 37536294). A further one compared it with combined oral contraceptive pills as part of the 2023 guideline update (PMID 37554096). GLP-1 medicines have a systematic review of their effects in PCOS (PMID 38444070) and a meta-analysis against metformin (PMID 31229399). Among supplements, inositol is the only one with evidence that fed a guideline, and the rest should be read against an umbrella review rather than against their own best trials. The inositol systematic review and meta-analysis was commissioned to inform the 2023 guideline update (PMID 38163998). A separate systematic review and meta-analysis reached a favourable conclusion (PMID 36703143). A randomised trial compared myoinositol with metformin against metformin alone (PMID 37265016), and a network meta-analysis placed inositol among other insulin sensitisers (PMID 34407851). For everything else, an umbrella review of meta-analyses graded the strength of the nutritional evidence in PCOS (PMID 36099162) and a network meta-analysis ranked supplements against each other (PMID 40611279). Those two are the honest entry point. Vitamin D has a systematic review on ovulation and pregnancy (PMID 37593349) and an umbrella review on lipids and hormones (PMID 39389530). N-acetylcysteine has a trial reporting effects on endocrine and metabolic profiles (PMID 39415242) and a randomised trial against l-carnitine (PMID 31273783). Omega-3 has a review of trials and cohorts (PMID 35180821). Berberine has an overview of systematic reviews (PMID 40269802), and its main PCOS-specific study is a one-group pretest-posttest design with no control group (PMID 34684666), which is worth knowing before reading it as evidence.

1. **Start from the guideline, not from a supplement aisle.** The 2023 international guideline is the document your clinician is most likely working from (PMID 37580314). 2. **Treat lifestyle as first-line and stop looking for the right diet.** The network meta-analysis ranked diets against each other and did not produce a winner (PMID 38388374, 39861440). 3. **Ask about cardiovascular and mental health screening, not only about periods.** Both are documented as elevated in PCOS and both are easy to leave out of an appointment (PMID 39119982, 28333286). 4. **If you are considering a supplement, consider inositol first**, because it is the only one whose evidence was commissioned to inform the guideline (PMID 38163998). 5. **Tell your prescriber before you start anything.** Most supplements used here act on insulin, which is what metformin does, so this is a stacking question rather than an addition. 6. **Say whether you are trying to conceive, avoiding conception, or neither.** It changes the answer more than any supplement below does.

Where the research supports a timeframe, the inositol and metformin trials pooled in the guideline work generally ran over **months** rather than weeks. The outcomes measured were hormonal and metabolic markers over that period (PMID 38163998, 37536294). The ovulation and pregnancy outcomes in the vitamin D review are measured per treatment cycle rather than on a calendar (PMID 37593349). No duration is offered for the diet comparisons, because the network meta-analysis ranked interventions rather than establishing how long any of them takes to work (PMID 38388374).

- **A guideline existing is not the same as it covering supplements.** The 2023 guideline commissioned a review of inositol (PMID 38163998). It did not commission one for most of the rest of this list, and their absence from the guideline is not the same as a negative finding. - **The umbrella review exists because individual meta-analyses in this area read stronger than the pooled certainty supports** (PMID 36099162). Reading a single favourable meta-analysis on a supplement here is the mistake the umbrella review was written to prevent. - **Berberine's PCOS-specific study has no control group** (PMID 34684666). A one-group pretest-posttest design cannot separate the intervention from time, regression to the mean, or the rest of what changed. The overview of systematic reviews is the better source (PMID 40269802). - **Inositol is not one substance.** Myo-inositol and D-chiro-inositol are different compounds in different ratios across products, and the trials do not all use the same thing (PMID 37265016, 34407851). - **Spearmint's anti-androgen evidence is two small trials, not a body of work** (PMID 19585478, 17310494). A review of plant-derived anti-androgens places it in context (PMID 23843810). It is included here because people take it, not because it is well supported. - **Almost none of this evidence is stratified by PCOS phenotype.** The condition is diagnosed by different combinations of criteria, and a trial population defined one way may not describe you.

- **Most supplements used for PCOS act on insulin, which is what metformin does.** If you take metformin, adding inositol or berberine is a stacking question. Raise it with **the clinician who prescribes your metformin** before starting, and ask what to watch for. - **If you are trying to conceive, or could conceive, this changes everything on the list.** Metformin use around conception and in the first trimester has its own systematic review and meta-analysis (PMID 40473092). That is a conversation for **your prescriber or fertility clinician**, not a decision to make from a supplement label. - **Anti-androgen medicines used for hirsutism are prescribed alongside contraception for a reason.** Guideline management and a current clinical review both cover this (PMID 37580314, 40200552). If you are taking or considering one, the pregnancy question belongs with **the clinician who prescribes it**. A targeted search for pregnancy-outcome evidence on spironolactone specifically did not return a citable source at the standard used elsewhere in this guide. No claim is made here about that drug beyond routing it to the prescriber. - **Do not add a spearmint product on the strength of its anti-androgen reputation if you take any hormonal medicine.** Raise it with **a pharmacist or your prescriber**, because a compound with a real hormonal effect and thin trial evidence is the combination that most often surprises people. - **Low mood, anxiety, or disordered eating in PCOS are common and are not a character flaw** (PMID 28333286). They are a reason to see **a clinician**, and they are treated, not managed with a supplement. - **Irregular bleeding that is new, heavy, or prolonged should go to a doctor** rather than to a supplement, because PCOS is not the only thing that causes it.

Resolving to an entity and being interaction-checkable are different things. The interaction catalogue keys on a collapsed name string rather than an entity id, so an entity can exist and still be checked against nothing. Resolves **and** has a catalogue key, so it can be interaction-checked: - `avelor:sup:berberine` - `avelor:sup:chromium` - `avelor:sup:omega-3`, `avelor:sup:omega-3-fish-oil` Resolves but has **no catalogue key**, so it displays as recognised and is checked against nothing: - `avelor:sup:inositol` - `avelor:sup:n-acetylcysteine` - `avelor:sup:omega-3-fatty-acids` No supplement entity, and none is invented here: - **Spearmint** exists only as medication-typed botanical extracts (`avelor:med:spearmint-extract`, `avelor:med:spearmint-allergenic-extract`). - **Vitamin D** has no supplement entity, only `avelor:med:vitamin-d`. This is the third guide in which its absence blocks the join, after bloodsugar and immune. The omega-3 case is the clearest illustration of the middle state anywhere in these guides. Three separate supplement entities exist for it. The catalogue holds omega rows under three different name strings. Two of the three entities collapse onto a catalogue key and one does not, so which entity a user's omega-3 resolves to decides whether it is checked at all. The single most consequential gap in this guide is inositol. It is the one supplement the guideline commissioned evidence for, and the one this guide tells people to consider first. It is also the one that cannot be interaction-checked against the metformin most of these readers are taking.

| PMID | Title | | --- | --- | | 37580314 | "Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome" | | 35934017 | "Polycystic ovary syndrome" | | 38922413 | "Global prevalence of polycystic ovary syndrome in women worldwide: a comprehensive systematic review and meta-analysis" | | 39119982 | "2023 International Evidence-Based Polycystic Ovary Syndrome Guideline Update: Insights From a Systematic Review and Meta-Analysis on Elevated Clinical Cardiovascular Disease in Polycystic Ovary Syndrome" | | 28333286 | "High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis" | | 39861440 | "The Role of Lifestyle Interventions in PCOS Management: A Systematic Review" | | 38388374 | "Ranking the dietary interventions by their effectiveness in the management of polycystic ovary syndrome: a systematic review and network meta-analysis" | | 37536294 | "The impact of metformin with or without lifestyle modification versus placebo on polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials" | | 37554096 | "Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis" | | 40473092 | "Preconception and first-trimester metformin on pregnancy outcomes in women with polycystic ovary syndrome: a systematic review and meta-analysis" | | 38444070 | "A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS" | | 31229399 | "GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis" | | 38163998 | "Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines" | | 36703143 | "Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials" | | 37265016 | "A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome" | | 34407851 | "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis" | | 36099162 | "Effects of nutrition on metabolic and endocrine outcomes in women with polycystic ovary syndrome: an umbrella review of meta-analyses of randomized controlled trials" | | 40611279 | "The effectiveness of nutritional supplements in improving polycystic ovary syndrome in women: a systematic review and network meta-analysis" | | 37593349 | "Effects of vitamin D supplementation on ovulation and pregnancy in women with polycystic ovary syndrome: a systematic review and meta-analysis" | | 39389530 | "Effect of vitamin D supplementation on lipid profile, and hormonal functions in polycystic ovary syndrome: An umbrella systematic review and meta-analysis" | | 39415242 | "N-acetylcysteine supplementation improves endocrine-metabolism profiles and ovulation induction efficacy in polycystic ovary syndrome" | | 31273783 | "Randomized controlled trial of N-acetylcysteine versus l-carnitine among women with clomiphene-citrate-resistant polycystic ovary syndrome" | | 35180821 | "Omega-3 supplementation in the treatment of polycystic ovary syndrome (PCOS) - a review of clinical trials and cohort" | | 40269802 | "Berberine and health outcomes: an overview of systematic reviews" | | 34684666 | "Berberine Phospholipid Is an Effective Insulin Sensitizer and Improves Metabolic and Hormonal Disorders in Women with Polycystic Ovary Syndrome: A One-Group Pretest-Post-Test Explanatory Study" | | 19585478 | "Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. A randomized controlled trial" | | 17310494 | "Effect of spearmint (Mentha spicata Labiatae) teas on androgen levels in women with hirsutism" | | 23843810 | "An update on plant derived anti-androgens" | | 40200552 | "Approach to the Patient: Hirsutism" |